The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Small cell lung cancer highlights at WCLC 2026
Giulia Pasello, MD, PhD, Istituto Oncologico Veneto IRCCS, Padua, Italy, comments on the highlights of the 2026 World Conference on Lung Cancer congress, particularly the plenary sessions focusing on small cell lung cancer (SCLC). Dr Pasello highlights that three important clinical trials presented in the plenary session showed promising results, including a clinical trial suggesting MRI may replace prophylactic cranial irradiation (PCI) as a standard of care, and two trials demonstrating the survival benefits of antibody-drug conjugates (ADCs) in the second-line treatment of SCLC. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I attend especially the plenary sessions of this conference and several news both in non-small cell lung cancer but what is more important in my opinion is small cell lung cancer. Small cell lung cancer is an uncommon cancer accounting for about 15% of all lung cancer. And for several decades, we had no news in terms of treatments. And in this particular plenary session of yesterday, Sunday, we had three important clinical trials...
I attend especially the plenary sessions of this conference and several news both in non-small cell lung cancer but what is more important in my opinion is small cell lung cancer. Small cell lung cancer is an uncommon cancer accounting for about 15% of all lung cancer. And for several decades, we had no news in terms of treatments. And in this particular plenary session of yesterday, Sunday, we had three important clinical trials. One, a very pragmatic clinical trial showing that both in metastatic and in locally advanced disease, the comparison between PCI and MRI probably showed an advantage in terms of clinical outcomes in the arm with MRI follow-ups, thus suggesting that the PCI will not be a standard of care in the next future. And the other two trials were two trials with two ADCs, important drugs, showing in the second line that they provide an advantage in terms of survival outcomes compared with the standard second line of chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
